Combination therapy of Crohn's disease with an interleukin 12/23 inhibitor and a targeted immunosuppressant: Clinical cases

Abstract

Several clinical studies, reviews, and clinical observations of dual biological therapy—the simultaneous use of two genetically engineered biological drugs and/or targeted immunosuppressants in Crohn's disease (CD)—have been published in recent years. The article presents clinical cases with dual biological therapy with upadacitinib and ustekinumab in patients with severe CD, which was preceded by genetically engineered biological therapy. After 26 weeks of combination therapy, all patients achieved clinical, endoscopic, and immunobiological remission of CD without serious adverse events.

Keywords

• crohn's disease
• upadacitinib
• ustekinumab